Otezla (apremilast) 60 Tablets 30mg

How It Works

Otezla (generic name apremilast) is a phosphodiesterase 4 (PDE4) inhibitor. It works by inhibiting the activity of PDE4, an enzyme that plays a role in the inflammatory process. By inhibiting PDE4, Otezla helps to reduce the production of inflammatory mediators such as tumor necrosis factor-alpha (TNF-alpha) and interleukin-23 (IL-23), which are involved in the pathogenesis of certain autoimmune diseases.

Side Effects

• Nausea
• Diarrhea
• Headache
• Upper respiratory tract infection
• Back pain

Indications

• Otezla is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for phototherapy or systemic therapy.
• It is also indicated for the treatment of active psoriatic arthritis in adults.

Contraindications

• Hypersensitivity to apremilast or any component of the formulation
• Severe renal impairment (creatinine clearance < 30 mL/min)
• Pregnancy (Otezla may cause fetal harm)

Price Comparison in Different Countries

Country	Price (per unit)	References
United States	$3,000	GoodRx
United Kingdom	?2,500	NHS
Australia	AUD 4,000	PBS Australia
Canada	CAD 3,500	CADTH
Germany	?2,500	Apotheken Umschau

Top 5 Global Brands

1. Pfizer
2. Roche
3. Novartis
4. Merck & Co.
5. Johnson & Johnson